OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
OptimizeRx CorporationNASDAQ: OPRX
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$3.2M, compared with $3.19M a year earlier. Trailing-twelve-month net change in cash was $3.6M.
Context
- Net change in cash amounted to 9.1% of revenue in FY2025, up 8.6 pp from a year earlier.
- Net change in cash increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$3.2M or moves back toward the trailing-twelve-month quarterly average of $899K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 9.99M USD
- Year-over-year change
- +2215.5%
- 4-year CAGR
- -39.4%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.99M | +2215.5% |
| FY2024 | 2024-12-31 | (472K) | +89.2% |
| FY2023 | 2023-12-31 | (4.36M) | +93.4% |
| FY2022 | 2022-12-31 | (66.47M) | -189.6% |
| FY2021 | 2021-12-31 | 74.16M | — |
Net Change in Cash vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +157.6% is the 5th highest of 10, against a peer median of +156.6%.
- Net change in cash amounts to 3.3% of revenue for OPRX, versus a peer median of 7.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$252.25M CAD | +407.1% | — | — | |
| LTM Mar 2026 | $51.55M USD | +48994.3% | — | 21.6% | |
| LTM Mar 2026 | $34.16M USD | +3903.5% | +503.9% | 871.5% | |
| LTM Mar 2026 | $25.3M USD | +321.0% | — | 7.3% | |
| LTM Feb 2026 | $14.74M USD | +156.6% | +12.1% | 18.3% | |
| LTM Mar 2026 | $10.43M USD | +124.5% | — | 8.2% | |
| LTM Mar 2026 | $3.6M USD | +157.6% | — | 3.3% | |
| LTM Mar 2026 | $3.14M USD | -91.1% | -32.0% | 3.9% | |
| LTM Mar 2026 | $2.8M USD | -19.4% | -24.1% | 2.0% | |
| LTM Mar 2026 | $45K USD | -94.4% | -85.3% | 0.0% | |
| Peer median (excluding OPRX) | — | +156.6% | -24.1% | 7.7% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 378.08K | (11.44M) | (17.57M) | (20.11M) | 5.13M |
| Depreciation & Amortization | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M |
| Deferred Income Tax | 0 | 0 | 0 | 1.45M | 1.21M |
| Stock-Based Compensation | 5.49M | 15.75M | 13.72M | 11.47M | 6.96M |
| Change in Working Capital | (7.19M) | 3.96M | (15.55M) | 921K | 816K |
| Accounts Receivables | (6.99M) | 2.28M | (8.71M) | (2.17M) | 460K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (603.09K) | 555.4K | 195K | (72K) | (520K) |
| Other Working Capital | 408.65K | 1.12M | (7.03M) | 3.16M | 876K |
| Other Non-Cash Items | 80K | 363.51K | 9.76M | 6.83M | 264K |
| Operating Cash Flow | 726.04K | 10.65M | (7.24M) | 4.89M | 18.72M |
| Capital Expenditures | (486K) | (244.57K) | (871K) | (112K) | (58K) |
| Acquisitions (Net) | 0 | (2M) | (80.41M) | 0 | 0 |
| Purchases of Investments | 0 | (55.93M) | (162.78M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 218.71M | 0 | 0 |
| Other Investing Activities | (385.68K) | (163.56K) | (774K) | (338K) | 126K |
| Investing Cash Flow | (486K) | (58.18M) | (25.34M) | (450K) | 68K |
| Debt Repayment | 0 | 0 | 36.02M | (4M) | (8M) |
| Common Stock Issued | 70.67M | 0 | 0 | 0 | 352K |
| Common Stock Repurchased | 0 | (20.02M) | (7.52M) | (911K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.25M | 1.07M | (278K) | 0 | (1.15M) |
| Financing Cash Flow | 73.92M | (18.95M) | 28.22M | (4.91M) | (8.8M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 74.16M | (66.47M) | (4.36M) | (472K) | 9.99M |
| Free Cash Flow | 240.04K | 10.41M | (8.11M) | 4.78M | 18.66M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.